The Lancet Haematology in conversation with
Lan-Lan Smith, Editor-in-Chief, Emma Cookson, Deputy Editor, and Daniela Marín, Senior Editor at The Lancet Haematology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from racial and ethnic disparities in leukaemia survival outcomes to resuscitation with blood products compared with saline, the link between mental health and lymphoma to haemolytic disease in newborns, and more.
ASH 2025 Preview - Expert Roundtable
Khaled Musallam, Bethany Samuelson Bannow, Mohamad Mohty, David Sallman, and Anna Sureda join us to share their expectations for the upcoming ASH 2025 congress, to be held from 6 to 9 December 2025 in Orlando, on classical and malignant haematology.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Arnon Kater and Sabina Kersting on the HOVON 158/NEXT STEP phase 2 trial testing a new first-line treatment regimen for chronic lymphocytic leukaemia
Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed by MRD-guided ibrutinib–obinutuzumab intensification.
Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00288-1/fulltext
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Ruben Mesa on ropeginterferon alfa-2b for hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia
Dr. Ruben Mesa (Executive Director of the Wake Forest Baptist Comprehensive Cancer Center) joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia.
Click here to read the full article
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
A panel of the authors on our Lancet Haematology-Lancet Regional Health Western Pacific Series on mature T-cell and natural killer-cell lymphomas
Today, on World Lymphoma Awareness Day, Professors Yok Lam Kwong, Wee Joo Chng, and Eric Tse join us in this joint episode of The Lancet Haematology and The Lancet Regional Health - Western Pacific to discuss their recent Series on advances in genomic techniques that have transformed the diagnosis, prognosis, and targeted treatment of mature T-cell and natural killer-cell lymphoma.
Read the Series:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00228-5/?dgcid=buzzsprout_icw_podcast_September_25_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky...
Lan-Lan Smith, Cheryl Lai, and Daniela Marín discuss the EHA, ICML, and ISTH conferences
June has been packed with interesting haematology conferences so the editorial team behind The Lancet Haematology have gathered to share their thoughts and reflect on their experiences at the European Hematology Association, International Conference on Malignant Lymphoma, and International Society on Thrombosis and Haemostasis meetings.
Read our conference round-ups here:
EHA: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00206-6/fulltext?dgcid=buzzsprout_icw_podcast_August_25_lanhae
ICML: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00207-8/fulltext?dgcid=buzzsprout_icw_podcast_August_25_lanhae
ISTH: https://www.thelancet.com...
Paolo Strati on off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma
Associate Professor Paolo Strati (Department of Lymphoma and Myeloma, and Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) joins us to discuss the results of a multicentre, open-label, phase 1 clinical trial of off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00142-5/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram...
A panel of the authors on our Adverse Events Series on adverse event reporting in haematological malignancies
With a growing number of treatment options for blood cancers, understanding the side effects from these treatments and how they affect patients is becoming ever more important. Join a panel of authors from The Lancet Haematology's latest series on Adverse Event reporting to discuss how we can improve clinical trial design and analysis, and translate this data to meaningful, patient-centric care.
Read the full series here:
https://www.thelancet.com/series-do/adverse-events-in-haematology-oncology?dgcid=buzzsprout_icw_podcast_13-06-25_lanhaeadverseevents25_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky...
Michael Northend on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma
Dr Michael Northend (University College London Hospitals NHS Foundation Trust, and Cancer Research UK & UCL Cancer Trials Centre, London, UK) joins us to discuss the long-term results of a randomised, phase 3 trial on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00034-1/fulltext?dgcid=buzzsprout_icw_podcast_28-04-25_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook...
Joanne Verweij and Romy Pothof on fetal and neonatal alloimmune thrombocytopenia
Dr Romy Pothof and Prof Joanne Verweij join us to discuss their development of an international consensus on the diagnosis and treatment of fetal and neonatal alloimmune thrombocytopenia.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00029-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Helene Schoemans, Elke Stienissen, and Kathy Goris on a consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe
Prof Helene Schoemans, Elke Stienissen, and Kathy Goris join us to discuss the importance of consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dawn Swan on air pollution and venous thromboembolism
Dr Dawn Swan joins us to discuss current knowledge and future perspectives on the possible association between air pollution and venous thromboembolism.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00291-6/fulltext?dgcid=buzzsprout_icw_podcast_general_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Leslie Skeith on low-dose aspirin for postpartum venous thromboembolism prophylaxis
Dr Leslie Skeith joins us to discuss the PARTUM pilot trial, comparing low-dose aspirin versus placebo in postpartum venous thromboembolism.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00338-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Neema Mayor and Caitlin Farrow on impact of patient ethnicity on haematopoeietic cell transplantation outcome in the United Kingdom
Dr Neema Mayor and Dr Caitlin Farrow from the Anthony Nolan Research Institute join us to discuss the findings of their study on the impact of patient ethnicity on haematopoietic cell transplantation outcomes in the United Kingdom.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00312-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv<...
Lancet Haematology 10 year anniversary - meet the editors
In a special 10 year anniversary podcast, Lan-Lan Smith, Yaiza del Pozo Martin, and Emma Cookson, the editorial team behind The Lancet Haematology, reflect on the last decade and give some insights into the editorial processes at The Lancet Group.
Read our Editorial:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00289-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com...
Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome
Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndrome patients.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Kim Linton on follicular lymphoma
Dr Kim Linton joins us to discuss the EPCORE NHL-1 trial testing monotherapy with the bispecific antibody epcoritamab for patients with relapsed or refractory follicular lymphoma.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00166-2?dgcid=buzzsprout_tlv_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Judy Truong on ferritin reference levels and iron deficiency
Dr Judy Truong join us to discuss ferritin reference intervals and how adoption of evidence-based ferritin clinical decision limits can help clinicians detect and treat iron deficiency, minimising propagation of related health inequity and social injustice in medicine.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00103-0?dgcid=buzzsprout_tlv_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv<...
Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML
Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00065-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Banu Aygun on sickle cell anaemia
Professor Banu Aygun joins us to discuss the REACH trial testing hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00078-4?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Sabine Braat and Katherine Fielding on haemoglobin thresholds to define anaemia
Dr Sabine Braat and Dr Katherine Fielding join us to discuss their study presenting new haemoglobin thresholds for defining anaemia.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00030-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Elisabeth Schorb on the MARTA phase 2 trial
Doctor Elisabeth Schorb joins us to discuss the MARTA phase 2 trial, treating older, fit patients with primary diffuse large B-cell CNS lymphoma with high-dose chemotherapy and autologous stem-cell transplantation.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00371-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Stephan Ehl on paediatric autoimmune lymphoproliferative immunodeficiencies
Professor Stephan Ehl joins us to discuss a prospective observational study on paediatric autoimmune lymphoproliferative immunodeficiencies.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Dr Sarah O'Brien on the PREVAPIX-ALL trial
Dr Sarah O'Brien joins Lan-Lan Smith to discuss results of the phase 3 PREVAPIX-ALL trial, which compares direct oral anticoagulant apixaban to low-molecular-weight-heparin for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00314-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https...
Enrico Lopriore on haemolytic disease of the fetus and newborn
Professor Enrico Lopriore joins us to discuss a trial testing darbepoetin alfa to prevent postnatal anaemia in infants with haemolytic disease of the fetus and newborn.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00285-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Meletios Dimopoulos on relapsed and refractory multiple myeloma
Professor Meletios Dimopoulos joins us to discuss two trials for patients with relapsed and refractory multiple myeloma - the first report of the DREAMM-3 phase 3 and long-term follow-up of the APOLLO phase 3 trial.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00243-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Eric Ohuma on haemoglobin concentrations and neonatal outcomes
Dr Eric Ohuma joins us to tell us about a study recently published in The Lancet Haematology on the association between maternal haemoglobin concentrations and maternal and neonatal outcomes.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00170-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Margaret Ragni on tranexamic acid to treat heavy menstrual bleeding
Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00119-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
...
Oreofe Odejide and Thomas Kuczmarski on mental health and lymphoma
Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00094-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Alok Srivastava on fitusiran for patients with haemophilia A and B
Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B.
Read the two trials:
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00284-2/fulltext?dgcid=buzzsprout_icw_podcast_buzzsprout_general
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B)
https://www.thelancet.com/journals/lanhae/article...
Emmanuela E Ambrose on stroke prevention in children with sickle cell disease
Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in Tanzania
Read the full article:
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE)
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Sumit Gupta on racial and ethnic disparities in leukaemia survival outcomes
Dr Sumit Gupta discusses how racial and ethnic disparities affect survival outcomes of children and young adults with acute lymphocytic leukaemia.
Read the full article:
Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Xiao-Jun Huang on cellular therapy in China
Professor Xiao-Jun Huang discusses this Lancet Haematology series on Cellular Therapy in China, covering the history, current research challenges, and future of HSCT and CAR T-cell therapies in China.
Read the Series papers:
Cellular therapy in China
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Glenn Pierce on haemophilia care in LMICs
Dr Glenn Pierce discusses the World Federation of Hemophilia’s Humanitarian Aid Program which provides access to haemophilia care in low-income and lower-middle-income countries.
Read the full Review:
Achieving access to haemophilia care in low-income and lower-middle-income countries
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Amy DeZern on the link between myelodysplastic syndrome and autoimmune disorders
Dr Amy DeZern discusses the link between myelodysplastic syndrome and autoimmune disorders and the need for a multidisciplinary approach for the treatment of patients who have both.
Read the full article:
Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Nicholas Crombie and Gavin Perkins on resuscitation with blood products compared with saline
Dr Nicholas Crombie and Professor Gavin Perkins discuss their randomised phase 3 trial in which they investigated resuscitation with blood products compared with saline in patients with trauma-related haemorrhagic shock receiving prehospital care.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Fredrik Schjesvold on OCEAN phase 3
Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide.
Read the full article:
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN)
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia
Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Raul Cordoba on haematological malignancies in older people
Dr Raul Cordoba discusses the joint Series between The Lancet Healthy Longevity and The Lancet Haematology on haematological malignancies in older people.
Read the full article:
A comprehensive approach to therapy of haematological malignancies in older patients
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Obiageli Nnodu and Dennis Chao on child mortality from sickle cell disease in Nigeria
Professor Obiageli Nnodu and Dr Dennis Chao join acting Deputy Editor Emma Cookson to talk about their new study describing modelling of child mortality as a result of sickle cell disease in Nigeria.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00191-5/fulltext
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Zuguo Mei and Gary Brittenham on iron deficiency
Senior Assistant Editor Ben Burwood speaks with Dr Zuguo Mei (Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA) and Dr Gary M Brittenham (Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY, USA) about their work defining physiologically based serum ferritin thresholds for iron deficiency.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00168-X/fulltext
Continue this conversation on social!
Follow us today at...
https://thelancet.b...
